Nicolas Primas

Nicolas Primas is a Lecturer at the Faculty of Pharmacy, Aix-Marseille University, where he contributes to the Radical Pharmacochemistry (PCR) Team. His academic role encompasses teaching Chemical Design of Medicines, Pharmacochemistry, Green Chemistry, and Public Healthcare – Hydrology courses across DFGSP2, DFGSP3, and DFASP1 pharmacy programs, reflecting his dual expertise in medicinal chemistry and pharmaceutical technology.

His research focuses on developing antiparasitic agents against neglected tropical diseases through heterocyclic molecule synthesis, particularly targeting malaria, leishmaniasis, and trypanosomiasis. Utilizing a Hit-to-Lead approach, he investigates structure-activity relationships, physicochemical properties, and pharmacokinetic parameters to identify molecular mechanisms of action and overcome resistance. Recent work emphasizes in vitro and in vivo validation using infected animal models, with strong translational focus on drug stability and formulation.

Analysis of his 2022–2024 publications reveals dominant themes: antiplasmodial quinazoline/imidazopyridine derivatives targeting Plasmodium kinases (e.g., PfPYK-1), optimization of microsomal stability/intestinal permeability for thienopyrimidones, and pediatric formulation stability studies. His work bridges medicinal chemistry and pharmaceutical technology, addressing artemisinin resistance and low-dose compounding challenges.

As part of the Radical Pharmacochemistry Team, Primas collaborates on Axis 2 projects (Bioactive Molecule Design) spanning organic synthesis, biological application development, and in vitro/in vivo validation. His laboratory integrates synthetic chemistry with pharmacological testing to advance anti-infective candidates toward preclinical development.